← TrialMatch
HomeTrials

FebriDx® Pediatric Validation Study

The primary objective of this study is to determine performance characteristics of the FebriDx® test in differentiating bacterial from non-bacterial etiology among febrile pediatric patients (2-11 years) presenting to the emergency department, urgent care center or primary care office with a suspected acute respiratory

Condition(s)Acute Respiratory Infections (ARIs)
StatusRecruiting
Study typeObservational
SummaryThe primary objective of this study is to determine performance characteristics of the FebriDx® test in differentiating bacterial from non-bacterial etiology among febrile pediatric patients (2-11 years) presenting to the emergency department, urgent care center or primary care office with a suspected acute respiratory tract infection.
Who can participateInclusion Criteria: * Signed informed consent by parent/guardian and Assent for ages 7-11 years * Exhibit or report of a new onset measured temperature (oral or tympanic) of greater than or equal to 100.4°F/38°C within 3 days (72 hours) of enrollment * Clinical suspicion for Acute Respiratory Infection beginning within 7 days before enrollment AND presents with at least one of the following new onset of symptoms: runny nose, nasal congestion, sore throat, cough, hoarse voice, shortness of breath / difficulty breathing Exclusion Criteria: * Unwilling to participate in 7-day follow-up or sign HIPAA waiver to obtain medical record if hospitalized * Immunocompromised state or taking immunosuppressive or chemotherapeutic medications in the last 30 days (e.g. oral / inhaled steroids, Methotrexat
Ages2 Years to 11 Years
SexAll
Lead sponsorLumos Diagnostics
LocationsColton, California, United States; Clearwater, Florida, United States; Lutz, Florida, United States; Tampa, Florida, United States; Huber Heights, Ohio, United States; Springfield, Ohio, United States (+4 more sites)
Start date2025-10-09
NCT IDNCT07211997
Official listinghttps://clinicaltrials.gov/study/NCT07211997

🔍 Search all trials →